Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ADIL with free AI briefings, catalyst countdowns, and dilution alerts.

ADIL · Adial Pharmaceuticals, Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

New ticker. Azora Therapeutics, Inc. (DE) now trades under the ticker AZR.
$22M Cash on Hand
10.2mo Cash Runway
Follow ADIL by email Get an email when ADIL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ADIL, unsubscribe in one click. Privacy

📣 What ADIL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
AT193 Hidradenitis Suppurativa Phase 1 · NCT04989517 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ADIL holds $22M in cash and short-term investments (as of Sep 30, 2026) and burns about $6.5M/quarter from operations, an estimated runway of 10.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ADIL files for a raise →

👥 Who Owns ADIL

Insiders 15.2% Institutions (20 holders) 30% Public and other holders 54.8%
HolderTypeShares% of sharesAs of
Matt Davidson
President and CEO, Director · +1.12M options
Insider 923,743 6.47% 2026-11-02
Julie Saiki
Chief Strategy Officer · +1,226 options
Insider 761,636 5.33% 2026-11-02
Coastlands Capital LP
10% owner
Insider 388,308 2.72% 2026-11-02
Cary J Claiborne
Chief Executive Officer, Director · +548,000 options
Insider 40,417 0.28% 2026-04-07
Tony Goodman
Chief Operating Officer, Director · +136,000 options
Insider 26,523 0.19% 2026-04-07
Vinay Shah
Chief Financial Officer · +49,000 options
Insider 17,325 0.12% 2026-04-07
Kevin Schuyler
Director · +40,000 options
Insider 9,447 0.07% 2026-04-07
Robertson H. Gilliland
Director · +40,000 options
Insider 9,185 0.06% 2026-04-07

Share count 14,286,311 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ADIL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ADIL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.